Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Indolent Lymphoid Malignancies
Status:
Terminated
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
1. To determine the maximally tolerated dose of anti-third party cytolytic T-lymphocytes,
defined as the dose which achieve engraftment without severe GVHD (graft-vs-host disease) at
90 days after allogeneic transplantation of CD34+ hematopoietic progenitor cells.
Secondary Objective:
1. Toxicity, response rate, time to progression and overall survival.